Friday 6 November 2026 Export BBIO’s income statement to Excel — free account

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.

Revenue: +192.6%
EPS: +67.5%
Free cash flow: +60.5%
Total debt: +4.21%

Quarter to September 2026, against a year earlier

74.28 0.01 +0.01%

Follow BBIO

Alert me

Market cap: $14.5B
P/E: 0.0×
Fwd P/E: −27.5×
Dividend yield: —
F-score: 3/9
Altman Z: −3.45
Beneish M: 8.17
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

BridgeBio Pharma, Inc. 10-K filed Feb 24, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed Feb 24, 2026 · accepted 4:51 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1A, Risk Factors, against the 10-K filed Feb 20, 2025: 21 added · 30 removed · 130 modified; 1 with only figures updated; 23 moved without change

BridgeBio Pharma, Inc. 10-K filed Feb 24, 2026

What changed

Stockrow Weekly